Mechanism of Two Classes of Cancer Mutations in the Phosphoinositide 3-Kinase Catalytic Subunit

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Science

• Publication date

  2007-07-13

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1126/SCIENCE.1135394PMID 17626883
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rare cancer-specific mutations in PIK3CA show gain of function

  2007cited by this paper
• Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers

  2007cited by this paper
• Mutations in the inter-SH2 domain of the regulatory subunit of phosphoinositide 3-kinase: effects on catalytic subunit binding and holoenzyme function

  2006cited by this paper
• Phosphoinositide 3-kinases as drug targets in cancer.

  2005cited by this paper
• Phosphoinositide 3-kinase in disease: timing, location, and scaffolding.

  2005cited by this paper
• Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells.

  2005cited by this paper
• PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.

  2005cited by this paper
• ConSurf 2005: the projection of evolutionary conservation scores of residues on protein structures

  2005cited by this paper
• Oncogenic PI3K deregulates transcription and translation

  2005cited by this paper
• Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.

  2005cited by this paper
• Mechanism of Constitutive Phosphoinositide 3-Kinase Activation by Oncogenic Mutants of the p85 Regulatory Subunit*

  2005cited by this paper
• Functional analysis of PIK3CA gene mutations in human colorectal cancer.

  2005cited by this paper
• Phosphoinositide 3-kinases as targets for therapeutic intervention.

  2004cited by this paper
• High Frequency of Mutations of the PIK3CA Gene in Human Cancers

  2004cited by this paper
• Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment.

  2004cited by this paper
• Targeting the PI3K-Akt pathway in human cancer: rationale and promise.

  2003cited by this paper
• Phosphoinositide 3-kinase signalling--which way to target?

  2003cited by this paper
• The structure of the inter-SH2 domain of class IA phosphoinositide 3-kinase determined by site-directed spin labeling EPR and homology modeling

  2003cited by this paper
• The p85 Regulatory Subunit Controls Sequential Activation of Phosphoinositide 3-Kinase by Tyr Kinases and Ras*

  2002cited by this paper
• The phosphoinositide 3-kinase pathway.

  2002cited by this paper
• Synthesis and function of 3-phosphorylated inositol lipids.

  2001cited by this paper
• Activation loop sequences confer substrate specificity to phosphoinositide 3-kinase alpha (PI3Kalpha ). Functions of lipid kinase-deficient PI3Kalpha in signaling.

  2001cited by this paper
• New Responsibilities for the PI3K Regulatory Subunit p85α

  2001cited by this paper
• Structural insights into phosphoinositide 3-kinase catalysis and signalling

  1999cited by this paper
• Regulation of the p85/p110 Phosphatidylinositol 3′-Kinase: Stabilization and Inhibition of the p110α Catalytic Subunit by the p85 Regulatory Subunit

  1998cited by this paper
• Regulation of the p85/p110alpha phosphatidylinositol 3'-kinase. Distinct roles for the n-terminal and c-terminal SH2 domains.

  1998cited by this paper
• Crystal structure of the PI 3-kinase p85 amino-terminal SH2 domain and its phosphopeptide complexes

  1996cited by this paper
• PI 3‐kinase: structural and functional analysis of intersubunit interactions.

  1994cited by this paper
• Phosphoinositide 3-kinase is activated by phosphopeptides that bind to the SH2 domains of the 85-kDa subunit.

  1993cited by this paper

• A new functional assay reveals that membrane binding is critical for overactivation of the phosphoinositide 3-kinase H1047R mutant.

  2026cites this paper
• Apocrine carcinoma of the breast: distinctive metabolic reprogramming and high‐frequency PIK3CA mutations revealed by molecular and immunohistochemical analysis

  2025cites this paper
• Lactylation orchestrates ubiquitin-independent degradation of cGAS and promotes tumor growth.

  2025cites this paper
• Cancer-Associated PIK3R1 Genetic Aberrations and Precision Medicine

  2025influential citation
• PIK3CA Mutations: Are They a Relevant Target in Adult Diffuse Gliomas?

  2025cites this paper
• Clinicopathological significance of common PIK3CA exon mutations in non-metastatic colorectal cancer.

  2025cites this paper
• Understanding the conformational dynamics of PI3Kα due to helical domain mutations: insights from Markov state model analysis

  2025cites this paper
• Activity and Dynamics of p110α are not Differentially Modulated by Regulatory Subunit Isoforms

  2025cites this paper
• Conventional and alternative approaches for targeting PIK3CA and PTEN alterations in head and neck, breast, and other cancers.

  2025cites this paper
• Phosphoinositide Metabolism: Biochemistry, Physiology and Genetic Disorders

  2025cites this paper
• Molecular basis for regulation of the class I phosphoinositide 3-kinases (PI3Ks), and their targeting in human disease.

  2025cites this paper
• Clinical and Morphological Features of ER-Positive HER2-Negative Breast Tumors with PIK3CA Mutations in Russian Patients

  2025cites this paper
• Oncogenic PI3Kα variants reveal graded conformational spectrum with mutation-specific cryptic pockets

  2025cites this paper
• POT, an optogenetics-based endogenous protein degradation system

  2025cites this paper
• Molecular Testing in Breast Cancer: A Guide for Surgical Pathologists.

  2025cites this paper
• Personalized Approaches to Lung Cancer Treatment: A Review of Targeted Therapies, Pharmacogenomics, and Combination Strategies

  2025cites this paper
• In Silico Discovery of a Novel Natural Product Targeting PI3Kα for the Treatment of Head and Neck Squamous Cell Carcinoma

  2025cites this paper
• Structural insights into isoform-specific RAS-PI3Kα interactions and the role of RAS in PI3Kα activation

  2025cites this paper
• Tumor antigen presentation and the associated signal transduction during carcinogenesis.

  2024cites this paper
• Leveraging altered lipid metabolism in treating B cell malignancies

  2024cites this paper
• An analysis of PIK3CA hotspot mutations and response to neoadjuvant therapy in breast cancer patients from four prospective clinical trials.

  2024cites this paper
• Unveiling the Role of PIK3R1 in Cancer: A Comprehensive Review of Regulatory Signaling and Therapeutic Implications.

  2024cites this paper
• A Comprehensive Review on Phosphatidylinositol-3-Kinase (PI3K) and its Inhibitors Bearing Pyrazole or Indazole Core for Cancer Therapy.

  2024cites this paper
• KBTBD2 controls bone development by regulating IGF-1 signaling during osteoblast differentiation

  2024cites this paper
• Dynamic molecular architecture and substrate recruitment of cullin3–RING E3 ligase CRL3KBTBD2

  2024cites this paper
• E4orf1: The triple agent of adenovirus – Unraveling its roles in oncogenesis, infectious obesity and immune responses in virus replication and vector therapy

  2024cites this paper
• Vertical inhibition of p110α/AKT and N‐cadherin enhances treatment efficacy in PIK3CA‐aberrated ovarian cancer cells

  2024cites this paper
• Molecular Basis of Oncogenic PI3K Proteins

  2024cites this paper
• Understanding PI3K/Akt/mTOR signaling in squamous cell carcinoma: mutated PIK3CA as an example

  2024cites this paper
• Regulatory role of some protein kinases in signal transduction pathways in heart health and disease

  2023cites this paper
• The mechanisms of class 1A PI3K and Wnt/β-catenin coupled signaling in breast cancer

  2023cites this paper
• Allosteric activation or inhibition of PI3Kγ mediated through conformational changes in the p110γ helical domain

  2023cites this paper
• Allosteric activation or inhibition of PI3Kγ mediated through conformational changes in the p110γ helical domain

  2023cites this paper
• Bioinformatics and In silico approaches to identify novel biomarkers and key pathways for cancers that are linked to the progression of female infertility: A comprehensive approach for drug discovery

  2023cites this paper
• Structural and mechanistic insights provided by single particle cryo-EM analysis of phosphoinositide 3-kinase (PI3Kα).

  2023cites this paper
• Multiple Mutations within Individual Oncogenes: Examples and Clinical Implications.

  2023cites this paper
• Role of m6A modification in regulating the PI3K/AKT signaling pathway in cancer

  2023cites this paper
• NMDAR-Arc signaling is required for Memory Updating and is disrupted in Alzheimer's Disease.

  2023cites this paper
• Epinephrine inhibits PI3Kα via the Hippo kinases

  2023cites this paper
• Independent effects of Src kinase and podoplanin on anchorage independent cell growth and migration

  2022cites this paper
• Oncogenic mutations of PIK3CA lead to increased membrane recruitment driven by reorientation of the ABD, p85 and C-terminus

  2022influential citation
• Functional network analysis of p85 and PI3K as potential gene targets and mechanism of oleanolic acid in overcoming breast cancer resistance to tamoxifen

  2022cites this paper
• Dynamic mRNA and miRNA expression of the head during early development in bighead carp (Hypophthalmichthys nobilis)

  2022cites this paper
• Frequency of PIK3CA mutations in different subsites of head and neck squamous cell carcinoma in southern Thailand

  2022cites this paper
• Control of phosphatidylinositol‐3‐kinase signaling by nanoscale membrane compartmentalization

  2022influential citation
• Signaling pathways, microenvironment, and targeted treatments in Langerhans cell histiocytosis

  2022cites this paper
• Class I PI3K Biology.

  2022cites this paper
• The mutational profiles and corresponding therapeutic implications of PI3K mutations in cancer.

  2022cites this paper
• Cryo-EM structures of cancer-specific helical and kinase domain mutations of PI3Kα

  2022cites this paper
• Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials

  2022cites this paper
• Screening and analysis of key genes in the biological behavior of bone mesenchymal stem cells seeded on gradient nanostructured titanium compared with native pure Ti

  2022cites this paper
• Nanobodies and chemical cross-links advance the structural and functional analysis of PI3Kα

  2022cites this paper
• Physiological expression of PI3K H1047R mutation reveals its anti-metastatic potential in ErbB2-driven breast cancer

  2022cites this paper
• The Importance of RTK Signaling Genes and their Inhibitors in Breast Cancer

  2022cites this paper
• Treating non-small cell lung cancer by targeting the PI3K signaling pathway

  2022cites this paper
• PIK3CA Gene Mutations in HNSCC: Systematic Review and Correlations with HPV Status and Patient Survival

  2022cites this paper
• Phospholipase C-related catalytically inactive protein enhances cisplatin-induced apoptotic cell death.

  2022cites this paper
• Nasopharyngeal Carcinoma Progression: Accumulating Genomic Instability and Persistent Epstein–Barr Virus Infection

  2022cites this paper
• PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway

  2021cites this paper
• Luminal A breast cancer resistance mechanisms and emerging treatments

  2021cites this paper
• RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy

  2021cites this paper
• A novel partially open state of SHP2 points to a “multiple gear” regulation mechanism

  2021cites this paper
• New derivatives of sulfonylhydrazone as potential antitumor agents: Design, synthesis and cheminformatics evaluation

  2021cites this paper
• Network Pharmacology Reveals Polyphyllin II as One Hit of Nano Chinese Medicine Monomers against Nasopharyngeal Carcinoma

  2021cites this paper
• The emerging role of non-coding RNAs in the regulation of PI3K/AKT pathway in the carcinogenesis process.

  2021cites this paper
• Structure of the phosphoinositide 3-kinase p 110 gp 101 2 complex reveals molecular mechanism of GPCR activation 3

  2021cites this paper
• Cancer-associated mutations in the p85α N-terminal SH2 domain activate a spectrum of receptor tyrosine kinases

  2021cites this paper
• Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma.

  2021cites this paper
• Cryo-EM structures of PI3Kα reveal conformational changes during inhibition and activation

  2021influential citation
• The Pathogenic Role of PI3K/AKT Pathway in Cancer Onset and Drug Resistance: An Updated Review

  2021cites this paper
• The Importance of Being PI3K in the RAS Signaling Network

  2021cites this paper
• The present and future of PI3K inhibitors for cancer therapy

  2021cites this paper
• SHORT Syndrome: Systematic Appraisal of the Medical and Dental Phenotype

  2021cites this paper
• Nuclear translocation of p85β promotes tumorigenesis of PIK3CA helical domain mutant cancer

  2021cites this paper
• Structure of the phosphoinositide 3-kinase p110γ-p101 complex reveals molecular mechanism of GPCR activation

  2021cites this paper
• Association with Longevity of Phosphatidylinositol 3-Kinase Regulatory Subunit 1 Gene Variants Stems from Protection against Mortality Risk in Men with Cardiovascular Disease

  2021cites this paper
• Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA

  2021cites this paper
• Potential Biological Targets Prediction, ADME Profiling, & Molecular Docking studies of Novel Steroidal Products from Cunninghamella Blakesleana.

  2021cites this paper
• Mutation-Associated Phenotypic Heterogeneity in Novel and Canonical PIK3CA Helical and Kinase Domain Mutants

  2020cites this paper
• PIK3CA mutation inhibition in hormone receptor-positive breast cancer: time has come.

  2020cites this paper
• Docking Studies and Antiproliferative Activities of 6-(3-aryl-2-propenoyl)-2(3H)-benzoxazolone Derivatives as Novel Inhibitors of Phosphatidylinositol 3-Kinase (PI3Kα).

  2020cites this paper
• Phosphorylation and Driver Mutations in PI3Kα and PTEN Autoinhibition

  2020cites this paper
• PI3K Driver Mutations: A Biophysical Membrane-Centric Perspective

  2020cites this paper
• Intracellular Signaling

  2020cites this paper
• Druggable Lipid Signaling Pathways

  2020cites this paper
• PIK3CA mutation inhibition in hormone receptor-positive breast cancer: time has come

  2020cites this paper
• Structural Biology in the Multi-Omics Era

  2020cites this paper
• Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers.

  2020cites this paper
• Allosteric Activation of PI3Kα Results in Dynamic Access to Catalytically Competent Conformations.

  2020cites this paper
• Drugging the Phosphoinositide 3-Kinase (PI3K) and Phosphatidylinositol 4-Kinase (PI4K) Family of Enzymes for Treatment of Cancer, Immune Disorders, and Viral/Parasitic Infections.

  2020cites this paper
• Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancer.

  2020cites this paper
• PIK3CA C-terminal frameshift mutations are novel oncogenic events that sensitize tumors to PI3K-α inhibition

  2020cites this paper
• The PTEN–PI3K Axis in Cancer

  2019cites this paper
• Several genotypes, one phenotype: PIK3CA/AKT1 mutation-negative hidradenoma papilliferum show genetic lesions in other components of the signalling network.

  2019cites this paper
• PIK3CA in cancer: The past 30 years.

  2019cites this paper
• Driver genes exome sequencing reveals distinct variants in African Americans with colorectal neoplasia

  2019cites this paper
• A novel carcinogenic PI3Kα mutation suggesting the role of helical domain in transmitting nSH2 regulatory signals to kinase domain.

  2019cites this paper
• Impact of p85α Alterations in Cancer

  2019cites this paper
• Akt-ing Up Just About Everywhere: Compartment-Specific Akt Activation and Function in Receptor Tyrosine Kinase Signaling

  2019cites this paper
• Hyperactivation of Torc1 Drives Resistance to the Pan-Her Tyrosine Kinase Inhibitor Neratinib in Her2-Mutant Cancers

  2019cites this paper